Maitri Enterprises Ltd
Incorporated in 1991, Maitri Enterprises Ltd is engaged in the business of Pharmaceutical products
- Market Cap ₹ 17.3 Cr.
- Current Price ₹ 39.4
- High / Low ₹ 51.3 / 23.4
- Stock P/E 49.5
- Book Value ₹ 12.1
- Dividend Yield 0.00 %
- ROCE 2.43 %
- ROE -9.48 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 3.25 times its book value
- Company has high debtors of 169 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Diversified Industry: Diversified - Medium / Small
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|
4.55 | 19.92 | 13.26 | 18.93 | 29.08 | |
4.47 | 19.23 | 12.76 | 18.68 | 26.77 | |
Operating Profit | 0.08 | 0.69 | 0.50 | 0.25 | 2.31 |
OPM % | 1.76% | 3.46% | 3.77% | 1.32% | 7.94% |
0.09 | 0.06 | 0.11 | 0.13 | -0.92 | |
Interest | 0.02 | 0.32 | 0.37 | 0.73 | 1.09 |
Depreciation | 0.05 | 0.09 | 0.07 | 0.06 | 0.08 |
Profit before tax | 0.10 | 0.34 | 0.17 | -0.41 | 0.22 |
Tax % | 40.00% | 32.35% | 94.12% | 9.76% | |
0.07 | 0.23 | 0.00 | -0.45 | -0.27 | |
EPS in Rs | 0.37 | 0.52 | 0.00 | -1.02 | -0.62 |
Dividend Payout % | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 61% |
TTM: | 74% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 133% |
Stock Price CAGR | |
---|---|
10 Years: | 23% |
5 Years: | % |
3 Years: | -28% |
1 Year: | -5% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | -9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|
Equity Capital | 4.40 | 4.40 | 4.40 | 4.40 |
Reserves | 0.57 | 0.57 | 0.12 | 0.93 |
5.72 | 6.34 | 10.54 | 8.24 | |
6.85 | 7.09 | 6.61 | 6.37 | |
Total Liabilities | 17.54 | 18.40 | 21.67 | 19.94 |
0.28 | 0.24 | 0.24 | 0.25 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.27 | 0.27 | 3.92 | 3.73 |
16.99 | 17.89 | 17.51 | 15.96 | |
Total Assets | 17.54 | 18.40 | 21.67 | 19.94 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
-0.39 | 0.02 | 0.06 | ||
-3.27 | -0.24 | -3.45 | ||
3.69 | 0.24 | 3.49 | ||
Net Cash Flow | 0.03 | 0.02 | 0.10 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Debtor Days | 163.81 | 205.62 | 168.71 | |
Inventory Days | 210.48 | 261.85 | 150.06 | |
Days Payable | 186.79 | 206.97 | 122.82 | |
Cash Conversion Cycle | 187.50 | 260.50 | 195.96 | |
Working Capital Days | 157.76 | 248.29 | 177.20 | |
ROCE % | 4.91% | 2.43% |
Documents
Announcements
-
Integrated Filing (Financial)
14 Feb - Board meeting outcome and financial results approved.
- Un-Audited Financial Results For The Quarter And Nine Months Ended On December 31, 2024 14 Feb
-
Board Meeting Outcome for Board Meeting Held On February 14, 2025
14 Feb - Board approved un-audited financial results for Q3 2024.
-
Announcement under Regulation 30 (LODR)-Change in Management
12 Feb - Appointment of Company Secretary & Compliance Officer.
-
Appointment of Company Secretary and Compliance Officer
12 Feb - Appointment of Company Secretary & Compliance Officer.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
a) Trading of Pharmaceutical & Medical Goods
b) Manufacturing of metal furniture
c) Trading of building materials